Search Result

Results for "

CX3CR1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CX3CR1 (7) Apoptosis (1) CCR (4) CXCR (1) HMG Family (2) Keap1-Nrf2 (2) NF-κB (2) NOD-like Receptor (NLR) (2) PCSK9 (2) Small Interfering RNA (siRNA) (3)
By Research Areas:	Cancer (6) Cardiovascular Disease (2) Endocrinology (8) Inflammation/Immunology (8)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Inhibitory Antibodies

Antibodies

Oligonucleotides

Targets Recommended: CX3CR1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13848

Rugocrixan Maximum Cited Publications 16 Publications Verification AZD8797; KAND567	CX3CR1 CXCR	Inflammation/Immunology Endocrinology Cancer
AZD8797 (KAND567) is an allosteric non-competitive and orally active antagonist of the human *CX3CR1* receptor; antagonizes CX3CR1 and CXCR2 with K_is of 3.9 and 2800 nM, respectively .

HY-107456

E6130 2 Publications Verification	CX3CR1	Inflammation/Immunology Endocrinology
E6130 is an orally active and highly selective *CX3CR1* modulator, that may be effective for treatment of inflammatory bowel disease.

HY-123918

JMS-17-2 10+ Cited Publications	CX3CR1	Endocrinology Cancer
JMS-17-2 is a potent and selective *CX3CR1* antagonist with an IC₅₀ of 0.32 nM. JMS-17-2 impairs metastatic seeding and colonization of breast cancer cells .

HY-P9928

Alirocumab 1 Publications Verification REGN 727; SAR 236553	PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1	Cardiovascular Disease Cancer
Alirocumab is an anti-PCSK9 human monoclonal antibody. Alirocumab inhibits PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and *Fractalkine/CX3CR1*. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation .

HY-160421

TREM2-IN-1	Apoptosis	Inflammation/Immunology Cancer
TREM2-IN-1 (OPA) is a TREM2 inhibitor derived from oxaliplatin and artesunate. TREM2-IN-1 can relieves immunosuppressive tumor microenvironment and enhancing chemical anticancer efficiency. TREM2-IN-1 deters the tumor growth in mice models bearing MC38 colorectal tumor by reducing the number of CD206 ⁺ and CX₃CR1 ⁺ immunosuppressive macrophages. TREM2-IN-1 also promotes the expansion and infiltration of immunostimulatory dendritic, cytotoxic T and natural killer cells .

HY-RS03379

CX3CR1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CX3CR1 Human Pre-designed siRNA Set A contains three designed siRNAs for CX3CR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CX3CR1 Human Pre-designed siRNA Set A CX3CR1 Human Pre-designed siRNA Set A

HY-RS03380

Cx3cr1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Cx3cr1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cx3cr1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cx3cr1 Mouse Pre-designed siRNA Set A Cx3cr1 Mouse Pre-designed siRNA Set A

HY-RS03381

Cx3cr1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Cx3cr1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cx3cr1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cx3cr1 Rat Pre-designed siRNA Set A Cx3cr1 Rat Pre-designed siRNA Set A

HY-168975

Fosrugocrixan	CX3CR1	Inflammation/Immunology
Fosrugocrixan is an antagonist for **CX3C chemokine receptor 1 (CX3CR1)** that exhibits anti-inflammatory activity .

HY-123918A

JMS-17-2 hydrochloride	CX3CR1	Endocrinology Cancer
JMS-17-2 hydrochloride is a potent and selective *CX3CR1* antagonist with an IC₅₀ of 0.32 nM. JMS-17-2 hydrochloride impairs metastatic seeding and colonization of breast cancer cells .

HY-15724A

Vercirnon sodium 3 Publications Verification GSK-1605786 sodium; CCX282-B sodium; Traficet-EN sodium	CCR	Inflammation/Immunology Endocrinology
Vercirnon (GSK1605786A) sodium is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon sodium inhibits CCR9-mediated Ca ²⁺ mobilization and chemotaxis on Molt-4 cells with IC₅₀ values of 5.4 and 3.4 nM, respectively. Vercirnon sodium is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC₅₀s>10 μM for all). Vercirnon sodium is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC₅₀ values of 2.8 and 2.6 nM, respectively .

HY-15724

Vercirnon 3 Publications Verification GSK-1605786; CCX282-B; Traficet-EN	CCR	Inflammation/Immunology Endocrinology
Vercirnon (GSK1605786A) is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon inhibits CCR9-mediated Ca ²⁺ mobilization and chemotaxis on Molt-4 cells with IC₅₀ values of 5.4 and 3.4 nM, respectively. Vercirnon is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC₅₀s>10 μM for all). Vercirnon is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC₅₀ values of 2.8 and 2.6 nM, respectively .

HY-P9928A

Alirocumab (anti-PCSK9) 1 Publications Verification REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)	PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1	Cardiovascular Disease Cancer
Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and *Fractalkine/CX3CR1*. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation .

HY-15724R

Vercirnon (Standard)	CCR	Inflammation/Immunology Endocrinology
Vercirnon (Standard) is the analytical standard of Vercirnon. This product is intended for research and analytical applications. Vercirnon (GSK1605786A) is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon inhibits CCR9-mediated Ca2+ mobilization and chemotaxis on Molt-4 cells with IC50 values of 5.4 and 3.4 nM, respectively. Vercirnon is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC50s>10 μM for all). Vercirnon is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC50 values of 2.8 and 2.6 nM, respectively .

HY-15724AR

Vercirnon sodium (Standard)	CCR	Inflammation/Immunology Endocrinology
Vercirnon (sodium) (Standard) is the analytical standard of Vercirnon (sodium). This product is intended for research and analytical applications. Vercirnon (GSK1605786A) sodium is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon sodium inhibits CCR9-mediated Ca2+ mobilization and chemotaxis on Molt-4 cells with IC50 values of 5.4 and 3.4 nM, respectively. Vercirnon sodium is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC50s>10 μM for all). Vercirnon sodium is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC50 values of 2.8 and 2.6 nM, respectively .

Cat. No.	Product Name	Target	Research Area

HY-P9928

Alirocumab 1 Publications Verification REGN 727; SAR 236553	PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1	Cardiovascular Disease Cancer
Alirocumab is an anti-PCSK9 human monoclonal antibody. Alirocumab inhibits PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and *Fractalkine/CX3CR1*. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation .

HY-P9928A

Alirocumab (anti-PCSK9) 1 Publications Verification REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)	PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1	Cardiovascular Disease Cancer
Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and *Fractalkine/CX3CR1*. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P84354

	CX3CR1 Antibody (YA4051) V28; CCRL1; GPR13; CMKDR1; GPRV28; CMKBRL1	ICC/IF, FC, ELISA	Human
	CX3CR1 Antibody (YA4051) is a mouse-derived and non-conjugated IgG2a antibody, targeting to CX3CR1. It can be applicated for ICC/IF, FC, ELISA assays, in the background of human.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

CX3CR1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
CX3CR1 Human Pre-designed siRNA Set A contains three designed siRNAs for CX3CR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cx3cr1 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Cx3cr1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cx3cr1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cx3cr1 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Cx3cr1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cx3cr1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.